MetaCap

Ultragenyx Pharmaceutical (RARE) vs First Tracks Biotherapeutics (TRAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

First Tracks Biotherapeutics is the larger company by market cap ($1.75 billion vs $1.68 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RARE-27.94%TRAX+119.16%
+186%+66%-55%
Apr 6, 20261 yearNov 20, 2026
RARE-29.27%TRAX+77.19%
+111%+33%-46%
Apr 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RARE versus TRAX key metrics
MetricRARETRAX
Share price$16.48$41.64
Market cap$1.68B$1.75B
1-day change-4.30%-6.34%
YTD return-28.35%—
1-year return-50.94%—
5-year return-78.45%—
Forward P/E11.50—
EPS (TTM)$-5.17$-4.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$673.00M—
Revenue growth (YoY)+20.18%—
Net income (latest FY)$-575.00M—
Operating margin-79.49%—
Net margin-85.44%—
52-week high$39.89$54.78
52-week low$12.73$14.72
Distance from 52-week high-58.69%-23.99%
Analyst consensusbuystrong_buy
Avg. price target upside+50.49%+80.52%
Average volume4.69M826.70K
Shares outstanding101.92M42.02M
Employees1,371104
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ultragenyx Pharmaceutical

RARE stock →

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees

About First Tracks Biotherapeutics

TRAX stock →

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees

RARE vs TRAX FAQ

Which is bigger, Ultragenyx Pharmaceutical or First Tracks Biotherapeutics?

First Tracks Biotherapeutics (TRAX) is larger, with a market capitalization of $1.75B compared with $1.68B for Ultragenyx Pharmaceutical (RARE).

Are Ultragenyx Pharmaceutical and First Tracks Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons